Skip to content
PeptideAI
Anecdotallongevitygut healthinflammation

Svetinorm

Liver peptide extract in capsule form, taken in monthly courses for hepatic support - typically by people with fatty liver, mildly raised enzymes or a history of heavy alcohol or medication load.

Also known as A-2, liver Cytomax, liver peptide bioregulator, Svetinorm A-2, Svetinorm, Svetinorm Lingual, A-2

Anecdotal — Community reports without controlled evidence. Treat the confident dosing charts accordingly.

No controlled human trials of Svetinorm exist, and no published liver enzyme or imaging data. The claims rest on manufacturer literature and the general Khavinson framework. If your liver enzymes are raised, get the cause diagnosed rather than treating a number with a supplement.

How it works

Svetinorm is peptide complex A-2, extracted from the liver of young calves at 10 mg per capsule. Manufacturer claims centre on restored hepatocyte protein synthesis, improved detoxification enzyme activity and support for regeneration after toxic injury. The synthetic Cytogen aimed at the same tissue is Livagen (Lys-Glu-Asp-Ala), whose actual published work is about chromatin decondensation in lymphocytes rather than anything hepatic. In short, the liver targeting of this whole sub-line rests on source tissue and naming convention rather than on demonstrated hepatic pharmacology.

Targets: Hepatocytes, Hepatic detoxification enzymes, Liver regeneration

Dosing

ProtocolDoseFrequencyRoute
Standard capsule course10-15 minutes before a meal.10 mg – 20 mgone to two capsules daily for 10 to 30 daysoral
  • · 10 mg of peptide complex per capsule.

Cycling

Ten to thirty days per course, two to three courses a year.

Work out your exact syringe units →

Pharmacology

Half-life
Not measured after oral dosing.
Onset
Nothing acute; liver enzyme changes, if any, would take weeks to show.
Routes
oral, sublingual
Molecule
Bovine liver-derived peptide complex in capsule form

Handling

Diluent
Not applicable - supplied as oral capsules.
Lyophilised
Not applicable - store capsules cool, dry and out of direct sunlight.
Reconstituted
Not applicable.
Light sensitive
Yes — keep it out of the light

Mixing

Nothing to reconstitute.

Side effects

  • uncommonMild digestive upset— Often excipient-related.
  • rareAllergic reaction to bovine protein— Animal-tissue-derived product.

Do not use if

  • Do not use this to justify continued alcohol intake or to substitute for treatment of viral hepatitis or MASH - that is the realistic way this product causes harm.
  • Known bovine protein allergy.
  • Pregnancy and breastfeeding - no data.
  • Haemochromatosis or iron overload - liver-tissue extracts have an unclear iron content and no compositional transparency.

Combining it

  • redundantlivagen — Livagen is the synthetic liver-directed Cytogen; overlapping claims.
  • synergytudca — Commonly stacked in liver-support protocols; TUDCA has considerably better evidence for hepatic endpoints.

What to monitor

  • · A liver panel - ALT, AST, GGT, ALP, bilirubin - before and about six weeks after a course. This is the one claim in the Cytomax line that a cheap blood test can actually check.
  • · Fibroscan or ultrasound if fatty liver is the reason you are using it.

Legal status

Sold as a food supplement in Russia and much of Europe; imported elsewhere as a dietary supplement. Not an approved drug.

References

  • Khavinson & Malinin, Gerontological Aspects of Genome Peptide Regulation (Karger monograph) (review)

Mechanism in depth

No primary literature exists for Svetinorm and none exists for the hepatic action of its synthetic counterpart either - Livagen's published work is chromatin decondensation in lymphocytes, not hepatology. So the entire liver sub-line of this programme, extract and synthetic together, rests on source tissue and naming convention. There is no hepatocyte culture study, no toxic-injury model, no transaminase data and no imaging endpoint for either product. The one honest mechanistic observation available is the portal-circulation point above: if any peptide fragment survives the gut, the liver is the first organ it meets at the highest concentration it will ever reach. That makes an orally dosed hepatic claim structurally more plausible than an orally dosed brain or retina claim, which is worth saying because it is the only pharmacokinetic argument in the Cytomax line that runs in the product's favour. It does not amount to evidence.

What usually goes wrong

The permission-slip failure is the specific one here. Someone with raised GGT and a fatty liver on ultrasound adds a liver-support capsule and treats it as covering the drinking or the oral steroid, and the underlying process continues silently for years. Metabolic liver disease progresses to fibrosis without symptoms and the point at which it announces itself is late. Get the cause diagnosed and get a FIB-4 calculated. The secondary issue is the iron point in the contraindications - an animal liver extract with no published compositional analysis is not something to take blind if your ferritin is high.

Bloodwork worth running

MarkerWhenWhy it matters
ALT, AST, GGT, ALP, bilirubin and albuminBaseline and six weeks after a course. Six weeks matters - ALT has a half-life of a couple of days and short retests are noise. Avoid alcohol for at least 72 hours before either draw, and avoid heavy resistance training for 48 hours, because muscle damage raises AST and ALT and produces convincing false signals.This is the one Cytomax where a cheap routine panel maps directly onto the claim, which makes it the one worth actually testing. It is also how you find out that nothing changed, which is a real answer.Act if: ALT persistently above about twice the upper limit of normal needs a diagnosis - viral hepatitis serology, an autoimmune screen, ferritin and transferrin saturation for haemochromatosis, and an ultrasound. Treating a raised number with a supplement instead of finding its cause is how people arrive at cirrhosis surprised.
FIB-4 score, calculated from age, AST, ALT and plateletsCalculate at baseline from your existing panel.Free, calculated from tests you already have, and it is the standard first-line fibrosis risk stratifier in metabolic liver disease. It tells you whether you have a cosmetic enzyme abnormality or the beginnings of scarring, and those are entirely different problems.Act if: FIB-4 above 1.3 under age 65, or above 2.0 over 65, warrants further fibrosis assessment such as elastography. That is a hepatology pathway, not a supplement decision.
Ferritin with transferrin saturationOnce at baseline in anyone with abnormal liver enzymes.Haemochromatosis is common, genetic, silently damages the liver, and is treated by venesection. It is also listed as a contraindication for this product on the reasonable grounds that a liver-tissue extract has undisclosed iron content.Act if: Transferrin saturation above 45 percent with raised ferritin warrants HFE genotyping. Do not take iron-containing animal tissue extracts while that question is open.

Pharmacokinetics

Metabolism
Presumed near-complete gastrointestinal proteolysis; any absorbed fragments pass first through the liver.
Elimination
Not characterised.

Receptor targets

  • No identified receptor or molecular target — None published

    Nothing has been characterised for this preparation, or for Livagen in liver tissue.

  • Hepatocyte protein synthesis, detoxification enzymes and regeneration (claimed)

    Manufacturer claim. I could not verify a single study of any hepatic endpoint for this product or its synthetic counterpart.

What to expect, and when

Nothing acute and nothing perceptible - liver disease and liver recovery are both silent. Weeks one to four: no expected change. Six weeks after a course: the earliest a transaminase retest is interpretable, and no change is the honest expectation. Months: any real improvement in liver enzymes over a course of this is far more likely to reflect the alcohol you also cut or the weight you also lost, which is why controlling those variables during the test period is the difference between an experiment and a story.

Stacking and comparisons

Svetinorm with Livagen is duplication of a claim that neither product has evidence for. With TUDCA the honest framing is that TUDCA has human data on hepatic endpoints and this does not. The interventions that actually change liver enzymes and liver fat are unglamorous and effective: alcohol reduction or cessation, 7-10 percent body weight loss in metabolic fatty liver, treating the underlying viral hepatitis, and reviewing hepatotoxic medications and supplements - including, ironically, some of the bodybuilding compounds that bring people to a liver-support product in the first place. If you are running oral 17-alpha-alkylated androgens, no peptide capsule offsets that and the only correct action is to stop.

Against TUDCA: TUDCA has human data in cholestatic liver disease and a defined bile-acid mechanism. Against silymarin: decades of trials with genuinely mixed results, but trials nonetheless. Against weight loss and alcohol cessation in metabolic fatty liver: those reverse steatosis and improve fibrosis, with effect sizes nothing in a capsule approaches. Against Livagen: the synthetic at least has a defined molecule and a real published experiment, even if that experiment is about lymphocytes.

Rough cost

$70–$200/month. A 20-capsule bottle covers ten to twenty days depending on dose. Indicative pricing for the branded Russian product, not verified against vendor listings in this session.

Genuinely uncertain

  • No indexed primary literature exists for Svetinorm under this name.
  • No hepatic study exists for the synthetic counterpart Livagen either - the liver designation across this entire sub-line is naming convention.
  • Oral bioavailability of the peptide complex has never been measured.
  • No liver enzyme, imaging or histological endpoint has ever been published for this product.
  • Iron content of the bovine liver extract is not disclosed, which is the basis of the haemochromatosis caution.
  • Composition is not published lot by lot.
  • Cost figures are indicative estimates and were not verified against live vendor listings in this session.

Papers